Santen

CompanyUnited States

Santen develops one asset, in phase 3 (sirolimus in aged). Mostly small molecule acting on autophagy, mTOR signalling and inflammation; based in the United States.

Assets
1
Furthest
Phase 3
Trials
7
Signals
0

Pipeline

1

  • sirolimus

    mTOR inhibitor delivered perivascularly via a collagen implant to improve arteriovenous fistula maturation.

    Phase 3Small moleculeAutophagymTOR signallingagedaging

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms5
  • Trials8
  • Signals4
  • Integrity notices1
  • Similar companies6

Updated 7 Oct 2026 · 59 sources

Intelligence